ARDS has been associated with the administration of other monoclonal antibodies, such as infliximab, gemtuzumab ozogamicin, and OKT3 and is believed to be directly mediated by release of proinflammatory cytokines.
ARDS
gemtuzumab ozogamicin
ARDS
OKT3
ARDS
infliximab